Phenmetrazine

Summary

Phenmetrazine (CHEMBL1201208) is an approved small-molecule sympathomimetic agent.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 177.24 Da · C11H15NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201208
Name	Phenmetrazine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4762
ChEBI	CHEBI:8067
Molecular formula	C11H15NO
Molecular weight	177.24
InChIKey	OOBHFESNSZDWIU-UHFFFAOYSA-N

SMILES: CC1C(OCCN1)C2=CC=CC=C2

IUPAC name: 3-methyl-2-phenylmorpholine

ChEBI definition: A member of the class of morpholines that is morpholine substituted with a phenyl group at position 2 and a methyl group at position 3.

Pharmacological roles (ChEBI): sympathomimetic agent.

Other ChEBI roles (chemical / environmental): metabolite.

Also known as: Fenmetrazina, Phenmetrazine, Trans-phenmetrazine, PHENMETRAZINE, phenmetrazine

Parent form; salt/anhydrous children: CHEMBL1200483

Patent coverage: 1,310 distinct patent families (5,042 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Sodium-dependent noradrenaline transporter, Alpha-1A adrenergic receptor, Sodium-dependent dopamine transporter.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).